Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 8.37 is in line with its 5-year average of 9.24, near the low end of its 5-year range (2.37–26.10).
As of the fiscal period ended Tuesday, June 30, 2026. 10.71% below its 12-month average of 9.37.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.37.
CURRENT RATIO
8.37
CURRENT RATIO AVG TTM
9.37
CURRENT RATIO AVG 3Y
10.73
CURRENT RATIO AVG 5Y
9.24
CURRENT RATIO AVG 10Y
11.22
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-10.71%
CURRENT VS 3Y AVG
-22.03%
CURRENT VS 5Y AVG
-9.38%
CURRENT VS 10Y AVG
-25.38%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.49
median of 688 covered companies
CURRENT VS SECTOR MEDIAN
+140.15%
vs the sector median at left
Denali Therapeutics Inc.
Market Cap
$3.13B
Current Ratio
8.37
TTM Avg
9.37
3Y Avg
10.73
5Y Avg
9.24
Market Cap
$3.09B
Current Ratio
12.12
TTM Avg
10.47
3Y Avg
8.70
5Y Avg
7.11
Market Cap
$3.09B
Current Ratio
64.07
TTM Avg
24.32
3Y Avg
16.73
5Y Avg
16.77
Market Cap
$3.09B
Current Ratio
2.92
TTM Avg
3.66
3Y Avg
6.49
5Y Avg
8.50
Market Cap
$2.89B
Current Ratio
12.02
TTM Avg
18.93
3Y Avg
12.46
5Y Avg
15.83
Market Cap
$3.42B
Current Ratio
17.91
TTM Avg
1.68
3Y Avg
1.68
5Y Avg
1.68
Market Cap
$3.45B
Current Ratio
3.39
TTM Avg
3.10
3Y Avg
3.17
5Y Avg
4.31
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.13B | 8.37 | 9.37 | 10.73 | 9.24 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 12.12 | 10.47 | 8.70 | 7.11 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | 64.07 | 24.32 | 16.73 | 16.77 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.09B | 2.92 | 3.66 | 6.49 | 8.50 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.89B | 12.02 | 18.93 | 12.46 | 15.83 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.42B | 17.91 | 1.68 | 1.68 | 1.68 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.42B | 9.63 | 11.21 | 9.89 | 7.80 |
| CareDx, Inc (CDNA)vs › | $3.43B | 4.58 | 3.40 | 3.98 | 4.25 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.45B | 3.39 | 3.10 | 3.17 | 4.31 |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 6.62 | 7.72 | 8.85 | 8.81 |
Current Ratio
8.37
Quick Ratio
8.32
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 8.37 |
| 2026-03-31 | 9.28 |
| 2025-12-31 | 9.16 |
| 2025-09-30 | 9.79 |
| 2025-06-30 | 10.27 |
| 2025-03-31 | 9.56 |
| 2024-12-31 | 8.46 |
| 2024-09-30 | 9.98 |
| 2024-06-30 | 12.46 |
| 2024-03-31 | 11.79 |
| 2023-12-31 | 13.65 |
| 2023-09-30 | 16.06 |
| 2023-06-30 | 17.65 |
| 2023-03-31 | 3.39 |
| 2022-12-31 | 3.77 |
| 2022-09-30 | 3.16 |
| 2022-06-30 | 3.20 |
| 2022-03-31 | 2.90 |
| 2021-12-31 | 2.37 |
| 2021-09-30 | 19.46 |
| 2021-06-30 | 26.10 |
| 2021-03-31 | 26.22 |
| 2020-12-31 | 20.86 |
| 2020-09-30 | 9.21 |
| 2020-06-30 | 9.57 |
| 2020-03-31 | 12.70 |
| 2019-12-31 | 9.48 |
| 2019-09-30 | 10.59 |
| 2019-06-30 | 10.66 |
| 2019-03-31 | 11.55 |
| 2018-12-31 | 14.67 |
| 2018-09-30 | 12.13 |
| 2018-06-30 | 12.17 |
| 2018-03-31 | 21.99 |
| 2017-12-31 | 28.92 |
| 2017-09-30 | 18.54 |
| 2017-06-30 | 17.55 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 19.98 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
